SEC 13F Intelligence

Managers / Q1 2026

Propel Bio Management, LLC

CIK 0001969764 · 11620 WILSHIRE BLVD.,, SUITE 350, LOS ANGELES, CA, 90025 · 908-507-9629

Reported Value
$159M
Q1 2026
Positions
38
Filings on Record
10
2019–present window
Filed
May 14, 2026
original filing

Summary

Propel Bio Management, LLC reported $159M in U.S.-listed holdings across 38 positions for Q1 2026.

Its largest position, PAGPEUR, represents 19.0% of the portfolio.

Compared with Q4 2025, the fund opened 22 new positions and exited 4.

Portfolio Metrics

Turnover
+20.6%
vs prior filed quarter
Top-10 Concentration
+58.3%
share of reported value
Largest Position
+19.0%
Plains GP Hldgs L P
New / Exited
22 / 4
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’23: $121MQ4 ’23Q1 ’24: $172MQ2 ’24: $154MQ2 ’24Q3 ’24: $172MQ4 ’24: $101MQ4 ’24Q1 ’25: $86MQ2 ’25: $82MQ2 ’25Q3 ’25: $100MQ4 ’25: $117MQ4 ’25Q1 ’26: $159Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 91.4%ADR: 5.1%Other: 3.5%
  • Common Stock · 91.4% · $145M
  • ADR · 5.1% · $8M
  • Other · 3.5% · $6M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2025 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
HTDCORCEPT THERAPEUTICS INCNEW+147.8K147.8K+$6M$6M
VORVOR BIOPHARMA INCNEW+314.5K314.5K+$6M$6M
OBIOORCHESTRA BIOMED HLDGS INCNEW+896.7K896.7K+$4M$4M
FDMT4D MOLECULAR THERAPEUTICS INNEW+380.4K380.4K+$4M$4M
OCULOCULAR THERAPEUTIX INCNEW+382.4K382.4K+$3M$3M
UPBUPSTREAM BIO INCNEW+341.8K341.8K+$3M$3M
AQSTAQUESTIVE THERAPEUTICS INCNEW+711.0K711.0K+$3M$3M
EYPTEYEPOINT INCNEW+215.8K215.8K+$3M$3M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2026

38 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1PAGPEURPLAINS GP HLDGS L Phistory →LTD PARTNR INT A19.02%$30M1.27M
2SP4PACHIEVE LIFE SCIENCES INChistory →COM7.17%$11M3.79M
3PHATPHATHOM PHARMACEUTICALS INChistory →COM5.90%$9M841.3K
4DCTHDELCATH SYS INChistory →COM NEW5.77%$9M979.7K
5HTDCORCEPT THERAPEUTICS INChistory →COM3.80%$6M147.8K
6ABEOABEONA THERAPEUTICS INChistory →COM NEW3.79%$6M1.33M
7VORVOR BIOPHARMA INChistory →COM NEW3.52%$6M314.5K
8KYTXKYVERNA THERAPEUTICS INChistory →COM3.52%$6M644.4K
9MISTMILESTONE PHARMACEUTICALS INhistory →COM3.20%$5M4.12M
10TCE2CELLDEX THERAPEUTICS INC NEWhistory →COM NEW2.61%$4M131.4K
11CMPSCOMPASS PATHWAYS PLChistory →SPONSORED ADS2.60%$4M742.0K
12VRDNVIRIDIAN THERAPEUTICS INChistory →COM2.58%$4M210.2K
13IVAINVENTIVA SAhistory →ADS2.52%$4M724.7K
14SABSSAB BIOTHERAPEUTICS INChistory →COM NEW2.45%$4M1.01M
15OBIOORCHESTRA BIOMED HLDGS INChistory →COM2.41%$4M896.7K
16FDMT4D MOLECULAR THERAPEUTICS INhistory →COM2.26%$4M380.4K
17OCULIS HOLDING AGORDINARY SHARES2.07%$3M122.2K
18OCULOCULAR THERAPEUTIX INChistory →COM2.03%$3M382.4K
19UPBUPSTREAM BIO INChistory →COM1.95%$3M341.8K
20AQSTAQUESTIVE THERAPEUTICS INChistory →COM1.86%$3M711.0K
21EYPTEYEPOINT INChistory →COM NEW1.76%$3M215.8K
22TRVITREVI THERAPEUTICS INChistory →COM1.67%$3M223.8K
23ZVRAZEVRA THERAPEUTICS INChistory →COM NEW1.66%$3M282.4K
24VTLUSDIMMUNIC INChistory →COM1.65%$3M2.34M
25CHRSCOHERUS ONCOLOGY INChistory →COM1.52%$2M1.42M
26OVIDOVID THERAPEUTICS INChistory →COM1.28%$2M921.5K
27PALIPALISADE BIO INChistory →COM1.26%$2M1.11M
28KLRSKALARIS THERAPEUTICS INChistory →COM1.08%$2M295.8K
29UNIQURE NVSHS1.08%$2M104.8K
30LONALEONABIO INCCOM0.94%$1M149.3K
31NUVBNUVATION BIO INCCOM CL A0.89%$1M329.3K
32MAZEMAZE THERAPEUTICS INCCOM0.82%$1M43.8K
33EVMNEVOMMUNE INCCOM SHS0.81%$1M55.7K
34CRVSCORVUS PHARMACEUTICALS INCCOM0.79%$1M85.8K
35ALDXALDEYRA THERAPEUTICS INCCOM0.78%$1M730.6K
36ARTVARTIVA BIOTHERAPEUTICS INCCOM0.60%$949,818146.4K
37CONNECT BIOPHARMA HLDGS LTDSHS0.35%$553,909209.5K
38MSCLSATELLOS BIOSCIENCE INCCOM0.04%$57,11610.1K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$159M38May 14, 202613F-HRchanges · EDGAR ↗
Q4 2025$117M20Feb 11, 202613F-HRchanges · EDGAR ↗
Q3 2025$100M16Nov 12, 202513F-HRchanges · EDGAR ↗
Q2 2025$82M16Aug 13, 202513F-HRchanges · EDGAR ↗
Q1 2025$86M18May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$101M21Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$172M21Nov 13, 202413F-HRchanges · EDGAR ↗
Q2 2024$154M25Aug 12, 202413F-HRchanges · EDGAR ↗
Q1 2024$172M29May 13, 202413F-HRchanges · EDGAR ↗
Q4 2023$121M34Feb 14, 202413F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.